Abstracts tagged "Administrative Data"

Abstract Number: 1291 • ACR Convergence 2023
Risk Factors for Major Adverse Cardiovascular Events and Malignancies in Patients with Rheumatoid Arthritis in a Real-World Setting in Japan
Toshitaka Hirano¹, Naonobu Sugiyama², Masato Hoshi¹, Joo-Young Jo³, Kichul Shin⁴ and Kunihiro Yamaoka⁵, ¹Pfizer Japan Inc, Tokyo, Japan, ²Pfizer Japan Inc, Japan, Japan, ³Pfizer Pharmaceuticals Korea Ltd, Seoul, South Korea, ⁴Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, South Korea, ⁵Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose: Patients (pts) with RA are at an increased risk of major adverse cardiovascular events (MACE) and malignancies vs the general population.1,2 However, risk factors…
Abstract Number: 2528 • ACR Convergence 2023
Current Trends in the Risk of Subsequent Fracture After Initial Fracture, and Post-Fracture Treatment Among Commercially Insured Postmenopausal Women in the United States
Min Kim¹, Vanessa C. Brunetti¹, Felicia Cosman², Jeffrey Curtis³, E Michael Lewiecki⁴, Matthew Phelan⁵, Peter Samai⁵, Michele McDermott¹, Tzu-Chieh Lin¹, M Alan Brookhart⁶ and Kathleen Hurwitz⁵, ¹Amgen, Inc., Thousand Oaks, CA, ²Columbia University, New York, NY, ³University of Alabama at Birmingham, Birmingham, AL, ⁴New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ⁵Target RWE, Durham, NC, ⁶Department of Population Health Sciences, Duke University, Durham, NC
Background/Purpose: Recent studies suggest that post-fracture pharmacologic management has been declining in the U.S. despite an increase in the burden of osteoporosis (OP). In light…
Abstract Number: 0833 • ACR Convergence 2023
Machine Learning Detected Healthcare Encounter Patterns Leading to Diagnosis of Juvenile Arthritis in a Population-Based Canadian Cohort
Lily Lim, Connor Hryhoruk, Ruth Ann Marrie, Christine Peschken, Carson Leung and Lisa Lix, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Increases in health care visits precede the first diagnosis code for inflammatory arthritis (IA) by an average of 5 years in adults, but it…
Abstract Number: 1324 • ACR Convergence 2023
Previous History of Serious Infection Is Associated with the Use of IL-6 Inhibitors in Rheumatoid Arthritis in Wales, UK
Roxanne Cooksey¹ and Ernest Choy², ¹Cardiff University, Cardiff, United Kingdom, ²Section of Rheumatology, Cardiff University, Cardiff, United Kingdom
Background/Purpose: Biologic therapy has revolutionised the treatment of rheumatoid arthritis (RA). Randomised control trials have shown that IL-6 inhibitors are superior to adalimumab, a TNF…
Abstract Number: 2529 • ACR Convergence 2023
Comparative Effectiveness of Denosumab versus Zoledronic Acid Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program
Jeffrey R Curtis¹, Tarun Arora², Ye Liu³, Vanessa C. Brunetti⁴, Tzu-Chieh Lin⁴, Leslie Spangler⁴, Robert K. Stad⁴, Michele McDermott⁴, Brian D. Bradbury⁴ and Min Kim⁴, ¹Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ²Foundation for Advancing Science, Technology, Education, and Research, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Amgen, Inc., Thousand Oaks, CA
Background/Purpose: Although clinical trials have shown that denosumab (Dmab) significantly increases bone mineral density at key skeletal sites more than zoledronic acid (ZA), evidence from…
Abstract Number: 0967 • ACR Convergence 2023
Overall Survival in Patients with versus Without Rheumatoid Arthritis Initiating Immune Checkpoint Inhibitors for Metastatic Non Small Cell Lung Cancer
Deanna Jannat-Khah¹, Jeffrey R Curtis², Fenglong Xie³, Ashish Saxena⁴ and Anne Bass⁵, ¹Hospital For Special Surgery, New York, NY, ²Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Immune checkpoint inhibitors (ICI) increase one-year survival in metastatic non-small cell lung cancer (mNSCLC) from 49% to 69% with chemotherapy-based regimens. Patients with rheumatoid…
Abstract Number: 1352 • ACR Convergence 2023
Similar Delivery Outcomes in Pregnant Patients with and Without Takayasu Arteritis – A Nationwide Inpatient Database Study
Yanint Raksadawan¹, Aravind Polam¹, Nattanicha Chaisrimaneepan² and Sabahat Usmani¹, ¹Weiss Memorial Hospital, Chicago, IL, ²Texas Tech University Health Sciences, Lubbock, TX
Background/Purpose: Takayasu's arteritis (TA) is a large vessel vasculitis which affects women of reproductive age. There is limited information about the effect of TA on…
Abstract Number: 2565 • ACR Convergence 2023
The Problem of Pain in Rheumatology: A Population-based Study of Annual Trends in Pain Management Modalities in Patients with Autoimmune Rheumatic Diseases in the United States, 2007-2021
Titilola Falasinnu¹, Di Lu² and Matthew Baker³, ¹Stanford School of Medicine, Palo Alto, CA, ²Stanford School of Medicine, Stanford, CA, ³Stanford University, Menlo Park, CA
Background/Purpose: Autoimmune rheumatic diseases (ARD) such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are salient causes of disability, functional limitations, reduced quality of…
Abstract Number: 0970 • ACR Convergence 2023
Comparison of Survival on Treatment and Severe Infection Among New Users of Biosimilar vs. Originator Biologics in Inflammatory Arthritis: Population-based Evidence from a Natural Experiment Due to a Policy Change
Diane Lacaille¹, J. Antonio Avina-Zubieta², Yufei Zheng², Na Lu² and Hui Xie³, ¹Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Canada, Vancouver, BC, Canada, ³Simon Fraser University, Richmond, BC, Canada
Background/Purpose: British Columbia's health policy mandated that all new anti-TNF initiations after June 2017 use biosimilars when available, providing the context for a natural experiment.…
Abstract Number: 1477 • ACR Convergence 2023
Clinical and Economic Burden of Herpes Zoster in Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study
Nikita Stempniewicz¹, Andrea Steffens², Kimvi Kim¹, Christopher Bell³, Mary DuCharme², Helen Trenz² and David Singer¹, ¹GlaxoSmithKline, Philadelphia, PA, ²Optum, Eden Prairie, MN, ³GlaxoSmithKline, US Value Evidence and Outcomes, Durham, NC
Background/Purpose: Herpes zoster (HZ) is characterized by a painful dermatomal rash and is associated with increased healthcare costs and reduced quality of life. Systemic lupus…
Abstract Number: 0979 • ACR Convergence 2023
Use and Discontinuation of Tumour Necrosis Factor Inhibitors Among Pregnant Women with Chronic Inflammatory Diseases
Leah K. Flatman¹, Sasha Bernatsky², Isabelle Malhamé³, Yvan St. Pierre², Olga Basso¹, Anick Bérard⁴ and Evelyne Vinet⁵, ¹McGill University, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³McGill University Health Centre, Montreal, QC, Canada, ⁴University of Montreal, Montreal, QC, Canada, ⁵McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Early consensus statements recommended discontinuing tumour necrosis factor inhibitors (TNFi) during pregnancy. Despite new guidelines recommending against this, the choice to stop TNFi pre-conception…
Abstract Number: 1544 • ACR Convergence 2023
Increased Risk of Severe Infection in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitides: A Population-based Trend Analysis
Kai Zhao¹, J. Antonio Avina-Zubieta², Hui Xie³, Natasha Dehghan⁴ and John Esdaile², ¹Arthritis Research Canada, Coquitlam, BC, Canada, ²Arthritis Research Canada, Vancouver, BC, Canada, ³Simon Fraser University, Richmond, BC, Canada, ⁴University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are a group of multisystem inflammatory diseases. One of the most serious and common side-effects of GC and…
Abstract Number: 0165 • ACR Convergence 2023
Hypothyroidism Is Associated with Worse Clinical and Utilization Outcomes After Primary Total Knee Arthroplasty
Sumanth Chandrupatla¹, Kranti Rumalla² and Jasvinder Singh¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Northwestern School of Medicine, Chicago, IL
Background/Purpose: Limited information is available regarding how medical comorbidities affect the outcomes of total knee arthroplasty (TKA). The association of medical comorbidities with post-TKA outcomes…
Abstract Number: 0999 • ACR Convergence 2023
Race, Payer, and Hospital Factors Are Associated with Post-primary Total Hip Arthroplasty Healthcare Utilization
Kranti Rumalla¹, Sumanth Chandrupatla² and Jasvinder Singh², ¹Northwestern School of Medicine, Chicago, IL, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Over 450,000 primary total hip arthroplasties (THA) are performed each year. One major indication for primary THA is the presence of osteoarthritis (OA). Patient…
Abstract Number: 1807 • ACR Convergence 2023
Hypothyroidism Impacts Clinical and Healthcare Utilization Outcomes After Primary Total Hip Arthroplasty
Sumanth Chandrupatla¹, Kranti Rumalla² and Jasvinder Singh¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Northwestern School of Medicine, Chicago, IL
Background/Purpose: Most data on the effect of comorbidities on primary total hip arthroplasty (THA) outcomes is focused on conditions that directly impact joint health, or…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].